688331 荣昌生物
已收盘 09-11 15:00:01
资讯
新帖
简况
【私募调研记录】巨杉资产调研云天励飞、荣昌生物
证券之星 · 09-09 08:13
【私募调研记录】巨杉资产调研云天励飞、荣昌生物
【私募调研记录】保银投资调研荣昌生物
证券之星 · 09-09 08:13
【私募调研记录】保银投资调研荣昌生物
荣昌生物：8月25日召开分析师会议，华泰证券、国联民生等多家机构参与
证券之星 · 09-09
荣昌生物：8月25日召开分析师会议，华泰证券、国联民生等多家机构参与
股市必读：荣昌生物新发布《荣昌生物关于参加科创板2026年半年度创新药行业集体业绩说明会的公告》
证券之星 · 09-09
股市必读：荣昌生物新发布《荣昌生物关于参加科创板2026年半年度创新药行业集体业绩说明会的公告》
荣昌生物：关于参加科创板2026年半年度创新药行业集体业绩说明会的公告
证券日报网 · 09-07
荣昌生物：关于参加科创板2026年半年度创新药行业集体业绩说明会的公告
东海证券：给予荣昌生物买入评级
证券之星 · 09-04
东海证券：给予荣昌生物买入评级
荣昌生物（688331）披露2026年第一次以集中竞价交易方式回购公司股份的进展公告，9月2日股价上涨3.28%
证券之星 · 09-02
荣昌生物（688331）披露2026年第一次以集中竞价交易方式回购公司股份的进展公告，9月2日股价上涨3.28%
荣昌生物(09995)：截至8月末累计回购4.1万股A股
智通财经 · 09-02
荣昌生物(09995)：截至8月末累计回购4.1万股A股
执行董事王玉晓减持荣昌生物(09995)1.35万股 每股作价约81.54港元
智通财经 · 09-02
执行董事王玉晓减持荣昌生物(09995)1.35万股 每股作价约81.54港元
执行董事王玉晓减持荣昌生物(09995)6500股 每股作价82港元
智通财经 · 09-01
执行董事王玉晓减持荣昌生物(09995)6500股 每股作价82港元
中金：维持荣昌生物(09995)跑赢行业评级 目标价112.92港元
智通财经 · 08-31
中金：维持荣昌生物(09995)跑赢行业评级 目标价112.92港元
每周股票复盘：荣昌生物（688331）Q2收入同比增808.6%
证券之星 · 08-30
每周股票复盘：荣昌生物（688331）Q2收入同比增808.6%
花旗：升荣昌生物(09995)目标价至127.7港元 续予“买入/高风险”评级
智通财经 · 08-26
花旗：升荣昌生物(09995)目标价至127.7港元 续予“买入/高风险”评级
中银国际下调荣昌生物目标价至114港元
同花顺 · 08-26
中银国际下调荣昌生物目标价至114港元
里昂：升荣昌生物(09995)目标价至144.8港元 维持“跑赢大市”评级
智通财经 · 08-26
里昂：升荣昌生物(09995)目标价至144.8港元 维持“跑赢大市”评级
荣昌生物（688331）2026年中报简析：营收净利润同比双双增长，盈利能力上升
证券之星 · 08-26
荣昌生物（688331）2026年中报简析：营收净利润同比双双增长，盈利能力上升
荣昌生物上半年赚逾46亿元背后：新药海外授权交易首付款贡献巨额利润
每日经济新闻 · 08-25
荣昌生物上半年赚逾46亿元背后：新药海外授权交易首付款贡献巨额利润
8月25日荣昌生物涨5.11%，万家行业优选LOF基金重仓该股
证券之星 · 08-25
8月25日荣昌生物涨5.11%，万家行业优选LOF基金重仓该股
荣昌生物（688331）披露2026年半年度报告，8月24日股价下跌7.24%
证券之星 · 08-24
荣昌生物（688331）披露2026年半年度报告，8月24日股价下跌7.24%
荣昌生物：上半年净利润46.62亿元，同比扭亏为盈
老虎资讯综合 · 08-24
荣昌生物：上半年净利润46.62亿元，同比扭亏为盈
加载更多
公司概况
公司名称：
荣昌生物制药(烟台)股份有限公司
所属行业：
医药制造业
上市日期：
2022-03-31
主营业务：
荣昌生物制药(烟台)股份有限公司的主营业务是研发、生产和销售医药产品、诊断试剂产品。公司的主要产品是泰它西普、维迪西妥单抗、RC28、RC148、RC118、RC278、RC288。
发行价格：
48.00
{"stockData":{"symbol":"688331","market":"SH","secType":"STK","nameCN":"荣昌生物","latestPrice":114.72,"timestamp":1789110001000,"preClose":114.07,"halted":0,"volume":4936537,"delay":0,"changeRate":0.0057,"floatShares":356000000,"shares":564000000,"eps":10.3131,"marketStatus":"已收盘","change":0.65,"latestTime":"09-11 15:00:01","open":113,"high":114.86,"low":110.2,"amount":555000000,"amplitude":0.0409,"askPrice":114.72,"askSize":1,"bidPrice":114.7,"bidSize":2,"shortable":0,"etf":0,"ttmEps":10.3131,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1789349400000},"marketStatusCode":5,"adr":0,"adjPreClose":114.07,"symbolType":"stock_kcb","openAndCloseTimeList":[[1789090200000,1789097400000],[1789102800000,1789110000000]],"highLimit":125.48,"lowLimit":102.66,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":564477483,"isCdr":false,"pbRate":7.79,"roa":"--","peRate":11.123716,"roe":"78.38%","epsLYR":1.29,"committee":0.61326,"marketValue":64757000000,"turnoverRate":0.0139,"status":0,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2026-09-14。","afterMarket":{"amount":502473.6,"volume":4380,"close":114.72,"buyVolume":0,"sellVolume":189,"time":1789112037746,"indexStatus":"已收盘 09-11 15:30:00","preClose":114.07},"hkstockBrief":{"symbol":"09995","market":"HK","secType":"STK","nameCN":"荣昌生物","latestPrice":73.75,"timestamp":1789114135010,"preClose":74.4,"halted":0,"volume":2176012,"delay":0,"premium":"-45.03"},"floatMarketCap":40828000000},"requestUrl":"/m/hq/s/688331","defaultTab":"news","newsList":[{"id":"2666031833","title":"【私募调研记录】巨杉资产调研云天励飞、荣昌生物","url":"https://stock-news.laohu8.com/highlight/detail?id=2666031833","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666031833?lang=zh_cn&edition=full","pubTime":"2026-09-09 08:13","pubTimestamp":1788912819,"startTime":"0","endTime":"0","summary":"截至2026年6月30日，公司拥有1231项专利，其中发明专利977项，一项获中国专利金奖。2）荣昌生物 调研纪要：2026年上半年营业收入为58.5亿元，同比增长433.11%，商业化销售13.4亿元，同比增长22.3%；销售费用5.5亿元，销售费用率同比下降7个百分点；研发费用4.1亿元，同比下降36%；净利润46.6亿元，同比扭亏为盈。机构简介：巨杉（上海）资产管理有限公司成立于2014年4月，是中国基金业协会会员，具备阳光私募基金管理人资格，及3+3投顾资格。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://fund.stockstar.com/RB2026090900007137.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688331","91213","09995","LU2148510915.USD","LU2328871848.SGD","BK1574","BK1161","BK0239","LU1064130708.USD","LU1969619763.USD","LU2488822045.USD","LU1064131003.USD","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666180303","title":"【私募调研记录】保银投资调研荣昌生物","url":"https://stock-news.laohu8.com/highlight/detail?id=2666180303","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666180303?lang=zh_cn&edition=full","pubTime":"2026-09-09 08:13","pubTimestamp":1788912812,"startTime":"0","endTime":"0","summary":"根据市场公开信息及9月8日披露的机构调研信息，知名私募保银投资近期对1家上市公司进行了调研，相关名单如下：1）荣昌生物 调研纪要：2026年上半年营业收入为58.5亿元，同比增长433.11%，商业化销售13.4亿元，同比增长22.3%；销售费用5.5亿元，销售费用率同比下降7个百分点；研发费用4.1亿元，同比下降36%；净利润46.6亿元，同比扭亏为盈。RC18在中国获批IgN和SjD，oMGⅢ期入组完成，海外MG全球Ⅲ期入组中，SjD Q2首例入组。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://fund.stockstar.com/RB2026090900007115.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09995","LU2488822045.USD","LU2328871848.SGD","BK1583","LU1064130708.USD","BK1574","LU2148510915.USD","688331","BK0239","LU1064131003.USD","BK1161","LU1969619763.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666372367","title":"荣昌生物：8月25日召开分析师会议，华泰证券、国联民生等多家机构参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2666372367","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666372367?lang=zh_cn&edition=full","pubTime":"2026-09-09 01:27","pubTimestamp":1788888446,"startTime":"0","endTime":"0","summary":"荣昌生物2026年中报显示，上半年度公司主营收入58.53亿元，同比上升433.11%；归母净利润46.62亿元，同比上升1137.06%；扣非净利润43.38亿元，同比上升1073.78%；其中2026年第二季度，公司单季度主营收入51.97亿元，同比上升808.6%；单季度归母净利润43.34亿元，同比上升2317.88%；单季度扣非净利润43.73亿元，同比上升2360.61%；负债率15.57%，投资收益128.7万元，财务费用2449.79万元，毛利率95.71%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090900002282.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1808992512.USD","BK1574","BK1564","LU0164865239.USD","01456","LU1979443071.USD","LU1064131003.USD","LU2488822045.USD","BK1583","BK0239","601688","LU0871576103.HKD","LU1328615791.USD","LU1580142542.USD","601456","BK0012","LU0531971595.HKD","BK1161","BK1147","688331","09995","BK0276","BK0183","BK0028","LU2328871848.SGD","LU1934453819.USD","LU2148510915.USD","LU1969619763.USD","BK0188","LU1781817850.SGD","LU0039217434.USD","LU1064130708.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666374484","title":"股市必读：荣昌生物新发布《荣昌生物关于参加科创板2026年半年度创新药行业集体业绩说明会的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2666374484","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666374484?lang=zh_cn&edition=full","pubTime":"2026-09-09 01:03","pubTimestamp":1788887000,"startTime":"0","endTime":"0","summary":"截至2026年9月8日收盘，荣昌生物报收于122.85元，上涨0.08%，换手率1.32%，成交量4.7万手，成交额5.73亿元。公司公告汇总：荣昌生物将于9月16日15:00–17:00通过上证路演中心参加科创板2026年半年度创新药行业集体业绩说明会。投资者可于2026年9月9日至9月15日16:00前通过上证路演中心网站或公司邮箱ir@remegen.com提交问题。说明会结束后可通过上证路演中心查看会议情况。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090900002105.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2148510915.USD","06978","BK0239","159992","BK1583","BK1574","BK1161","LU1064131003.USD","LU1064130708.USD","LU2488822045.USD","LU2328871848.SGD","09995","LU1969619763.USD","688331"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665731933","title":"荣昌生物：关于参加科创板2026年半年度创新药行业集体业绩说明会的公告","url":"https://stock-news.laohu8.com/highlight/detail?id=2665731933","media":"证券日报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665731933?lang=zh_cn&edition=full","pubTime":"2026-09-07 18:43","pubTimestamp":1788777780,"startTime":"0","endTime":"0","summary":"证券日报网讯9月7日，荣昌生物发布公告称，公司计划于2026年9月16日15：00-17：00参加2026年半年度科创板创新药行业集体业绩说明会，就投资者关心的问题进行交流。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/hk/2026-09-07/doc-iniqyzxs9619866.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/hk/2026-09-07/doc-iniqyzxs9619866.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["688331","09995","BK1161","BK1583","LU1064130708.USD","LNGR","LU2148510915.USD","LU2488822045.USD","LU2328871848.SGD","MEDX","IBBQ","BK0239","LU1064131003.USD","159992","BK1574","KSTR","06978","LU1969619763.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664800103","title":"东海证券：给予荣昌生物买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2664800103","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664800103?lang=zh_cn&edition=full","pubTime":"2026-09-04 08:32","pubTimestamp":1788481936,"startTime":"0","endTime":"0","summary":"东海证券股份有限公司杜永宏近期对荣昌生物进行研究并发布了研究报告《公司简评报告：业绩亮眼，研发国际化加速推进》，给予荣昌生物买入评级。 荣昌生物 投资要点 公司业绩表现靓丽。最新盈利预测明细如下：该股最近90天内共有8家机构给出评级，买入评级7家，增持评级1家；过去90天内机构目标均价为161.61。本文数据来源于东海证券股份有限公司，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090400007902.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09995","688331","161027"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664536817","title":"荣昌生物（688331）披露2026年第一次以集中竞价交易方式回购公司股份的进展公告，9月2日股价上涨3.28%","url":"https://stock-news.laohu8.com/highlight/detail?id=2664536817","media":"证券之星","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664536817?lang=zh_cn&edition=full","pubTime":"2026-09-02 22:04","pubTimestamp":1788357855,"startTime":"0","endTime":"0","summary":"截至2026年9月2日收盘，荣昌生物报收于123.57元，较前一交易日上涨3.28%，最新总市值为697.52亿元。近日，荣昌生物发布《关于2026年第一次以集中竞价交易方式回购公司股份的进展公告》。公告显示，公司于2026年7月19日召开董事会，审议通过以集中竞价交易方式回购公司股份的方案，回购期限为2026年7月19日至2027年7月18日，拟回购金额为2,500万元至5,000万元，回购价格不超过149元/股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090200042603.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1969619763.USD","LU1064131003.USD","BK0239","09995","LU2488822045.USD","688331","LU2328871848.SGD","LU2148510915.USD","BK1161","BK1583","LU1064130708.USD","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664819216","title":"荣昌生物(09995)：截至8月末累计回购4.1万股A股","url":"https://stock-news.laohu8.com/highlight/detail?id=2664819216","media":"智通财经","labels":["buyback"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664819216?lang=zh_cn&edition=full","pubTime":"2026-09-02 20:01","pubTimestamp":1788350479,"startTime":"0","endTime":"0","summary":"智通财经APP讯，荣昌生物(09995)发布公告，截至2026年8月31日，公司通过上海证券交易所交易系统以集中竞价交易方式累计回购公司股份4.1万股，占公司总股本的比例为0.0073%，回购成交的最高价为109.99元/股，最低价为108.30元/股，支付的资金总额为人民币447.67万元(不含交易佣金等交易费用)。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1491170.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159982","09995","LU2328871848.SGD","BK1161","07233","LU1064130708.USD","82846","83188","LU1064131003.USD","BK0239","LU2488822045.USD","83130","BK1147","02827","BK1583","BK1574","03130","02846","03188","399300","LU2148510915.USD","688331","LU1969619763.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664819359","title":"执行董事王玉晓减持荣昌生物(09995)1.35万股 每股作价约81.54港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2664819359","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664819359?lang=zh_cn&edition=full","pubTime":"2026-09-02 19:38","pubTimestamp":1788349091,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新资料显示，8月27日，执行董事王玉晓减持荣昌生物(09995)1.35万股，每股作价81.5352港元，总金额约为110.07万港元。减持后最新持股数目为2227.86万股，最新持股比例为10.68%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1491147.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09995","LU1064131003.USD","LU2328871848.SGD","BK1583","BK1161","LU2488822045.USD","BK0239","EWH","LU2148510915.USD","LU1064130708.USD","LU1969619763.USD","BK1574","688331"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664557708","title":"执行董事王玉晓减持荣昌生物(09995)6500股 每股作价82港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2664557708","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664557708?lang=zh_cn&edition=full","pubTime":"2026-09-01 19:35","pubTimestamp":1788262545,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新资料显示，8月26日，执行董事王玉晓减持荣昌生物(09995)6500股，每股作价82港元，总金额为53.3万港元。减持后最新持股数目为2229.21万股，最新持股比例为10.69%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1490537.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688331","09995","LU1064130708.USD","BK1161","EWH","LU1969619763.USD","BK0239","LU2328871848.SGD","LU2148510915.USD","LU1064131003.USD","LU2488822045.USD","BK1574","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663250100","title":"中金：维持荣昌生物(09995)跑赢行业评级 目标价112.92港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2663250100","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663250100?lang=zh_cn&edition=full","pubTime":"2026-08-31 09:39","pubTimestamp":1788140361,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中金发布研报称，维持荣昌生物跑赢行业评级，维持2026/2027年归母净利润预测40.25/5.83亿元不变。基于DCF估值，维持目标价112.92港元不变，相较当前股价有34.8%上行空间。公司收到与艾伯维关于RC148合作授权协议的6.5亿美元首付款拉动技术授权收入大幅增加，1H26业绩符合该行预期。此外泰它西普已被纳入《国家基本药物目录》内“免疫系统用药”，该行认为有望进一步提升在基层市场的用药可及性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1489190.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["EWH","09995","688331"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663461010","title":"每周股票复盘：荣昌生物（688331）Q2收入同比增808.6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663461010","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663461010?lang=zh_cn&edition=full","pubTime":"2026-08-30 03:33","pubTimestamp":1788031989,"startTime":"0","endTime":"0","summary":"截至2026年8月28日收盘，荣昌生物报收于119.73元，较上周的125.5元下跌4.6%。本周，荣昌生物8月26日盘中最高价报125.66元。股本股东变化截至2026年6月30日，公司股东户数为2.42万户，较3月31日增加4489.0户，增幅22.76%。公司公告汇总荣昌生物2026年半年度报告摘要显示，报告期末公司总资产为9,847,249,925.82元，较上年度末增长35.86%；归属于上市公司股东的净资产为8,314,075,106.28元，较上年度末增长130.38%。荣昌生物披露2026年上半年募集资金存放与实际使用情况。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083000001135.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","LU1969619763.USD","LU2148510915.USD","LU1064130708.USD","LU1064131003.USD","BK0239","09995","BK1583","LU2328871848.SGD","LU2488822045.USD","BK1161","688331"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662791545","title":"花旗：升荣昌生物(09995)目标价至127.7港元 续予“买入/高风险”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2662791545","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662791545?lang=zh_cn&edition=full","pubTime":"2026-08-26 17:12","pubTimestamp":1787735524,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，花旗发布研报称，荣昌生物(09995)上半年收入同比增长433%，亏转盈赚46.6亿元人民币。管理层表示，剔除BD收入后上半年净亏损约2,600万元人民币，预期剔除BD收入后，2026财年可实现收支平衡。目标价由105港元升至127.7港元，续予“买入/高风险”评级。该行表示，泰它西普及维迪西妥单抗展现强劲的按季销售增长，又相信RC148交易可重塑公司的增长轨道。该行上调公司2026至28年的收入预测3%、22%及18%，并将每股盈测调升至8.5元、2.2元及2.7元人民币。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1486027.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688331","EWH","09995"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662716228","title":"中银国际下调荣昌生物目标价至114港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2662716228","media":"同花顺","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662716228?lang=zh_cn&edition=full","pubTime":"2026-08-26 16:48","pubTimestamp":1787734080,"startTime":"0","endTime":"0","summary":"中银国际发布研报称，维持荣昌生物（688331.SH）“买入”评级，由于竞争激烈，因此下调维迪西妥单抗的长期价值，并推迟RC28的销售贡献，不过，上述负面影响部分被泰它西普更快的销售增长、 ...","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/hks/20260826/c679307835.shtml","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20260826/c679307835.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["688331"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662796640","title":"里昂：升荣昌生物(09995)目标价至144.8港元 维持“跑赢大市”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2662796640","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662796640?lang=zh_cn&edition=full","pubTime":"2026-08-26 16:16","pubTimestamp":1787732166,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，里昂发布研报称，荣昌生物(09995)2026年第二季销售同比增长808.6%，净利43.34亿元人民币，两者均超出市场预期，受惠于RC18强劲销售势头及RC148对外授权费用贡献。管理层维持2026年全年营运盈亏平衡指引。公司RC148、RC18及RC48的海外进展按计划进行。考虑到业绩表现，该行修订预测，将荣昌生物2026财年销售预测上调52.6%，2027和2028财年预测下调23.8%/12.1%。2026财年净利预测上调136.8%，2027和2028财年预测下调65.1%/25.2%;并将目标价由136.9港元上调至144.8港元。维持“跑赢大市”评级。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1485935.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09995","EWH","688331"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662750819","title":"荣昌生物（688331）2026年中报简析：营收净利润同比双双增长，盈利能力上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2662750819","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662750819?lang=zh_cn&edition=full","pubTime":"2026-08-26 06:16","pubTimestamp":1787696181,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期荣昌生物发布2026年中报。截至本报告期末，公司营业总收入58.53亿元，同比上升433.11%，归母净利润46.62亿元，同比上升1137.06%。按单季度数据看，第二季度营业总收入51.97亿元，同比上升808.6%，第二季度归母净利润43.34亿元，同比上升2317.88%。本报告期荣昌生物盈利能力上升，毛利率同比增幅13.86%，净利率同比增幅294.53%。本文数据来源于荣昌生物2026年中报，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082600009599.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688331","09995"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662773013","title":"荣昌生物上半年赚逾46亿元背后：新药海外授权交易首付款贡献巨额利润","url":"https://stock-news.laohu8.com/highlight/detail?id=2662773013","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662773013?lang=zh_cn&edition=full","pubTime":"2026-08-25 21:40","pubTimestamp":1787665201,"startTime":"0","endTime":"0","summary":"凭借一笔价值数十亿美元的海外授权交易，荣昌生物（SH688331）在2026年上半年实现了业绩逆转。8月24日晚间，荣昌生物披露的半年报显示，今年上半年，公司归母净利润逾46亿元，而去年同期亏损4.50亿元。这一同比“扭亏为盈”的亮眼成绩，主要得益于公司与国际制药巨头艾伯维就新药RC148达成的独家授权协议，仅首付款一项便为公司带来了巨额的技术授权收入。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608253853325244.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608253853325244.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1064130708.USD","LU2148510915.USD","BK1574","LU2488822045.USD","LU2328871848.SGD","BK1161","09995","688331","LU1064131003.USD","BK0239","LU1969619763.USD","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662782245","title":"8月25日荣昌生物涨5.11%，万家行业优选LOF基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2662782245","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662782245?lang=zh_cn&edition=full","pubTime":"2026-08-25 16:37","pubTimestamp":1787647026,"startTime":"0","endTime":"0","summary":"证券之星消息，8月25日荣昌生物涨5.11%，收盘报122.37元，换手率3.24%，成交量11.52万手，成交额13.88亿元。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共121家，其中持有数量最多的公募基金为万家基金的万家行业优选LOF。万家行业优选LOF的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082500033763.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2148510915.USD","688331","LU1969619763.USD","LU2328871848.SGD","BK1583","BK1161","LU1064130708.USD","LU1064131003.USD","LU2488822045.USD","BK0239","BK1574","09995","160916"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661274908","title":"荣昌生物（688331）披露2026年半年度报告，8月24日股价下跌7.24%","url":"https://stock-news.laohu8.com/highlight/detail?id=2661274908","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661274908?lang=zh_cn&edition=full","pubTime":"2026-08-24 22:01","pubTimestamp":1787580099,"startTime":"0","endTime":"0","summary":"截至2026年8月24日收盘，荣昌生物报收于116.42元，较前一交易日下跌7.24%，最新总市值为657.16亿元。近日，荣昌生物制药（烟台）股份有限公司披露2026年半年度报告。2026年上半年，公司实现营业收入5,853,293,736.77元，同比增长433.11%；利润总额为4,662,874,654.00元；归属于上市公司股东的净利润为4,662,283,356.30元；归属于上市公司股东的扣除非经常性损益的净利润为4,338,351,346.93元。研发投入占营业收入的比例为7.08%，较上年同期下降51.87个百分点。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082400036624.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688331","LU1064130708.USD","LU2488822045.USD","09995","BK1161","BK1583","LU1969619763.USD","BK0239","LU2148510915.USD","LU2328871848.SGD","LU1064131003.USD","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177027604","title":"荣昌生物：上半年净利润46.62亿元，同比扭亏为盈","url":"https://stock-news.laohu8.com/highlight/detail?id=1177027604","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1177027604?lang=zh_cn&edition=full","pubTime":"2026-08-24 17:31","pubTimestamp":1787563888,"startTime":"0","endTime":"0","summary":"8月24日，$荣昌生物(09995)$公告，2026年上半年营业收入58.53亿元，同比增长433.11%；归属于上市公司股东的净利润46.62亿元，2025年同期亏损4.5亿元，实现扭亏为盈；归属于上市公司股东的扣除非经常性损益的净利润43.38亿元，2025年同期亏损4.46亿元。","market":"hk","thumbnail":"https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"荣昌生物：上半年净利润46.62亿元，同比扭亏为盈","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","LU1064130708.USD","LU1064131003.USD","688331","09995","BK1161","LU1969619763.USD","BK1574","LU2488822045.USD","BK0239","LU2328871848.SGD","LU2148510915.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1789168800972,"stockEarnings":[{"period":"1week","weight":-0.0766},{"period":"1month","weight":-0.1159},{"period":"3month","weight":0.0072},{"period":"6month","weight":0.0243},{"period":"1year","weight":0.0413},{"period":"ytd","weight":0.4747}],"compareEarnings":[{"period":"1week","weight":-0.0107},{"period":"1month","weight":-0.0148},{"period":"3month","weight":-0.0356},{"period":"6month","weight":-0.0506},{"period":"1year","weight":0.0033},{"period":"ytd","weight":-0.0203}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"荣昌生物制药(烟台)股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"24209人(较上一季度增加22.76%)","perCapita":"14700股","listingDate":"2022-03-31","address":"山东省烟台市福山区中国(山东)自由贸易试验区烟台片区烟台开发区北京中路58号","registeredCapital":"56447万元","survey":" 荣昌生物制药(烟台)股份有限公司的主营业务是研发、生产和销售医药产品、诊断试剂产品。公司的主要产品是泰它西普、维迪西妥单抗、RC28、RC148、RC118、RC278、RC288。","listedPrice":48},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"荣昌生物(688331)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供荣昌生物(688331)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"荣昌生物,688331,荣昌生物股票,荣昌生物股票老虎,荣昌生物股票老虎国际,荣昌生物行情,荣昌生物股票行情,荣昌生物股价,荣昌生物股市,荣昌生物股票价格,荣昌生物股票交易,荣昌生物股票购买,荣昌生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"荣昌生物(688331)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供荣昌生物(688331)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}